A Gene Therapy Study for Hemophilia B

Gene Therapy, Open-Label, Dose-Escalation Study of SPK-9001 (Adeno-Associated Viral Vector With Human Factor IX Gene) in Subjects With Hemophilia B

Category & Conditions:
Rare Diseases
Medicine:
fidanacogene elaparvovec (PF-06838435)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
C0371005
Open Plain Language Summary Result:Click here